👀 Ones to watch: The MOST undervalued stocks to buy right nowSee Undervalued Stocks

AbbVie Earnings, Revenue Beat in Q2

Published 07/31/2020, 07:45 AM
© Reuters.  AbbVie Earnings, Revenue Beat in Q2

© Reuters. AbbVie Earnings, Revenue Beat in Q2

US500
-1.09%
SPY
-1.10%
ABBV
-0.65%

Investing.com - AbbVie (NYSE:ABBV) reported on Friday second quarter earnings that beat analysts' forecasts and revenue that topped expectations.

AbbVie announced earnings per share of $2.34 on revenue of $10.43B. Analysts polled by Investing.com anticipated EPS of $2.2 on revenue of $9.93B.

AbbVie shares are up 8% from the beginning of the year , still down 5.17% from its 52 week high of $101.28 set on July 17. They are outperforming the S&P 500 which is up 0.48% from the start of the year.

AbbVie shares gained 2.25% in pre-market trade following the report.

AbbVie follows other major Healthcare sector earnings this month

AbbVie's report follows an earnings beat by J&J on July 16, who reported EPS of $1.67 on revenue of $18.34B, compared to forecasts EPS of $1.49 on revenue of $17.61B.

Roche Holding ADR had beat expectations on July 23 with second quarter EPS of $1.45 on revenue of $15.27B, compared to forecast for EPS of $1.42 on revenue of $15.69B.

Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads.

Should you invest $2,000 in ABBV right now?

With ABBV making headlines, savvy investors are asking: Is it truly valued fairly? In a market full of overpriced darlings, identifying true value can be challenging. InvestingPro's advanced AI algorithms have analyzed ABBV alongside thousands of other stocks to uncover hidden gems. These undervalued stocks, potentially including ABBV, could offer substantial returns as the market corrects. In 2024 alone, our AI identified several undervalued stocks that later surged by 30 or more. Is ABBV poised for similar growth? Don't miss the opportunity to find out.

Reveal Undervalued Stocks Now

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.